Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the second quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company engages in the ...

Objective: Despite several observational studies attempting to investigate the potential association between type 1 diabetes mellitus (T1DM) and the risk of digestive cancers, the results remain ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

San Diego’s Dexcom began sales this week of Stelo ... A one-off purchase of a single pack with two sensors — which lasts 30 days — costs $99. There’s also a monthly subscription option ...

San Diego’s Dexcom began sales this week of Stelo ... A one-off purchase of a single pack with two sensors — which lasts 30 days — costs $99. There’s also a monthly subscription option, which costs ...